Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy Regimens

NCT04089657 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER_GOV

Sponsor class

Conditions

Advanced Metastatic Gastric Cancer

Interventions

DRUG: Apatinib Mesylate
DRUG: Sintilimab

Sponsor

Fujian Cancer Hospital